MAIA
MAIA Biotechnology, Inc. (AMEX)
Healthcare — Biotechnology
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Strong Buy
1.0 / 5
2 analysts
$1.43
$-0.01 (-0.69%)
Target:
$12.14
(748.6%)
Sign in to add MAIA to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $86.95M |
| P/E Ratio (TTM) | - |
| Forward P/E | 1.28 |
| EPS (TTM) | $-0.68 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -148.29% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $12.14 |
| Analysts | 2 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 67.4 |
| Beta | 0.24 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.19 |
| 52-Week Low | $0.87 |
| 50-Day Avg | $1.33 |
| 200-Day Avg | $1.49 |
| Avg Volume | 753.1K |
| Volume | 255.7K |
Performance Analysis
BULLISHMAIA shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 24% of its 52-week range.
+
RSI at 67.4 shows positive momentum.
+
Wall Street consensus is "Strong Buy" from 2 analysts.
+
Average analyst target of $12.13 implies 748.6% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report